CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Novo-backed Windward Bio targets $1 billion valuation in US IPO

By Reuters News

Nov 9 (Reuters) - Swiss drug developer Windward Bio Group AG is targeting a valuation of up to $1 billion in its US initial public offering, as a strong run for the biotech IPO market extends into November.

Here are some other details:

  • Basel, Switzerland-based Windward is seeking to raise up to $185.3 million in the US IPO by selling roughly 10.3 million shares priced between $16 and $18, it said on Monday

  • The healthcare industry, which is seen as a defensive sector, has anchored the fall IPO window this year as choppy market conditions and rising borrowing costs weigh on activity from other sectors

  • Drug developer Rezera also kicked off its US IPO roadshow last week and is expected to go public in New York this week

  • Windward has raised $310 million in equity financing from Novo Holdings and other healthcare investors including, OrbiMed, Blue Owl and RTW Investments.

  • The firm is developing antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease and atopic dermatitis

  • French drugmaker Sanofi SASY.PA has agreed to purchase $50 million of shares and pre-funded warrants in a private placement

  • Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are underwriting the offering

  • Windward Bio will list on the Nasdaq under the symbol “WWB”

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.